Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03310684 · ClinicalTrials.gov registry record

Pediatric Primary Hypertension and the Renin-Angiotensin System (PHRAS)

A clinical trial, sponsored by Wake Forest University Health Sciences.

Completed
Registry status
35
Enrollment target

NCT03310684 is a clinical trial that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 35 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03310684 has completed, sponsored by Wake Forest University Health Sciences.

COMPLETED
Registry status
35 participants
Enrollment target

Study Summary

Pediatric primary hypertension is increasingly common, occurring in 5-10% of normal-weight children and up to 25% of children with obesity. It is a risk factor for adult cardiovascular and renal disease. But even during childhood, hypertension is associated with significant morbidity, including cognitive impairment and organ damage. In the heart and kidneys, this organ damage is characterized by thickened heart muscle (left ventricular hypertrophy) and spillage of protein in the urine (albuminuria). Obese children are also at risk for fatty liver disease. However, the cause of pediatric primary hypertension, the role of obesity, and the mechanisms behind heart and kidney injury are poorly understood. Due to these limitations, there are no first-line medications, and treatment is often inadequate. An altered renin-angiotensin system may cause primary hypertension and related organ damage. Evidence suggests uric acid, FGF23, klotho, and obesity play a role in renin-angiotensin system-mediated injury. An improved comprehension of the pathophysiology of pediatric primary hypertension could enhance clinical care by targeting treatment to the cause of disease and informing novel measurement of organ damage.

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2018-12-03
Est. Completion 2023-04-26

Sponsor

Wake Forest University Health Sciences

1,140 total trials

What the Registry Record Tells You About NCT03310684

The ClinicalTrials.gov registry entry for NCT03310684 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT03310684 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03310684 about?

NCT03310684 is a clinical study titled "Pediatric Primary Hypertension and the Renin-Angiotensin System (PHRAS)". Pediatric primary hypertension is increasingly common, occurring in 5-10% of normal-weight children and up to 25% of children with obesity. It is a risk factor for adult cardiovascular and renal disease. But even during childhood, hypertension is associated with significant morbidity, including cogn...

What is the current status of trial NCT03310684?

This trial is currently completed. The enrollment target is 35 participants. The study started on 2018-12-03. Estimated completion is 2023-04-26.

Who is sponsoring clinical trial NCT03310684?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.